Aytu BioScience Reemphasizes Coronavirus Stock Status With Potential Treatment

By Chris Lange Published Apr 27, 10:19AM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Aytu BioScience Reemphasizes Coronavirus Stock Status With Potential Treatment — © nito100 / Getty Images

Aytu BioScience Inc. (NASDAQ: AYTU) shares made an incredible gain to start the week following the firm’s announcement in regards to a coronavirus treatment. Specifically, Aytu announced that it had signed an agreement with Sterling Medical Devices to finalize the development of Healight, a novel endotracheal catheter, as a potential treatment for coronavirus.

Last week, the company announced a licensed exclusive worldwide rights agreement to the Healight technology from Cedars-Sinai for all endotracheal and nasopharyngeal indications. The patent-pending Healight platform has been in development since 2016 by the Medically Associated Science and Technology team at Cedars-Sinai. Following their preclinical findings that Healight may be a safe and effective antiviral and antibacterial treatment, the team engaged Sterling to rapidly develop a novel endotracheal device to help combat coronavirus.

Ultimately, management believes the Healight platform technology has the potential to positively affect outcomes for critically ill patients infected with coronavirus and other infections. Aytu, with support of the team at Cedars-Sinai, is working with the U.S. Food and Drug Administration (FDA) to determine an expedited regulatory process to potentially enable near-term use of the technology initially as a coronavirus intervention for critically ill intubated patients.

Josh Disbrow, board chair and chief executive of Aytu BioScience, commented:

The Aytu team is very pleased to be working with Sterling Medical on this important development program and in the fight against coronavirus. Sterling has a stellar reputation as a best-in-class medical device product firm with more than 21 years of experience, over 1,100 projects engineered, with none failing to receive FDA regulatory approval upon submission. Our team is actively engaged with our colleagues at Sterling in an effort to finalize the device development, with hope of enabling human use in the very near future.

[nativounit]

Aytu BioScience stock traded up about 33% to $1.86 Monday morning. The 52-week range is $0.34 to $2.99, and the consensus price target is $3.75.

[recirclink id=684512][wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.